Synergys emphasizes “in-license and development”, rather than carrying out in-house early stage discovery research. By focusing its efforts on in-licensing early stage product candidates for development, Synergys expects to conserve cash and reduce costs by maintaining and managing a small but competent organizational structure. Synergys’ business model is designed to enable early return of investment for investors by focusing on developing pre-clinical stage antibody candidates to early value inflection point and forming partnerships with companies with late stage biologics development resources, expertise and market presence.
"Though bitter, good medicine cures illness. Though it may hurt, loyal criticism will have beneficial effects".
-- Matthew Prior